Illumina to Shed Cancer|Test Maker Grail After Antitrust Battle

Illumina to divest cancer test maker Grail after antitrust battles | Reuters

Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

Illumina to Shed Cancer-Test Maker Grail After Antitrust Battle - WSJ

Illumina said it will pursue the divestiture through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of next ...

FTC Orders Illumina to Divest Cancer Detection Test Maker GRAIL ...

Real world evidence of Illumina's past behavior reinforces the Commission's antitrust concerns. For instance, Illumina gave GRAIL special ...

Illumina to Shed Grail in 12 Months Without EU Court Win

Illumina, a prominent life sciences company, finds itself on the clock as it must divest Grail, a cancer test maker, within 12 months, ...

Illumina To Shed Cancer-Test Maker Grail After Antitrust Battle ...

Illumina To Shed Cancer-Test Maker Grail After Antitrust Battle. Published by: dailynews. Published on: December 17, 2023. Read the full story on The Wall ...

Statement Regarding Illumina's Decision to Divest Grail

Illumina, Inc. · Federal Trade Commission Bureau of Competition Director Henry Liu issued the following statement: · “This is a major win for the ...

Illumina Ordered by EU to Unwind Grail Acquisition - WSJ

European Union's antitrust watchdog orders life-sciences company to shed U.S. cancer-test developer it acquired in 2021.

Shaoul Sussman on LinkedIn: Illumina to Shed Cancer-Test Maker ...

Illumina said it will divest itself of cancer blood test maker Grail. The move follows the gene-sequencing company's loss in its legal battle ...

Illumina's Antitrust Battles to End With Divestiture of Cancer Test ...

Illumina is done fighting in the courts to keep cancer-detection company Grail. The gene-sequencing giant had previously pledged to divest ...

WSJ Business News on X: "Gene-sequencing company Illumina ...

... Grail, following Illumina's loss in its legal battle against U.S. antitrust ... Illumina to Shed Cancer-Test Maker Grail After Antitrust Battle.

Grail bets big on flagship cancer test after spin-off from Illumina - Mint

US cancer diagnostic test maker Grail, which will list its shares on the Nasdaq on Tuesday after being spun out of Illumina, is betting that commercial ...

Illumina to Divest Cancer Test Maker Grail After Antitrust Battles

(Reuters) - Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled ...

The Wall Street Journal on LinkedIn: Illumina to Shed Cancer-Test ...

Illumina said it will divest itself of cancer blood test maker Grail. The move follows the gene-sequencing company's loss in its legal battle ...

San Diego-Based Illumina to Divest Cancer Test Maker Grail After ...

Illumina said it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and European antitrust enforcers for ...

Illumina Loses Long Antitrust Battle, Readies to Divest GRAIL

Following a U.S. appeals court decision, the company said it is preparing to divest GRAIL through a third-party sale or capital markets ...

Illumina to divest cancer test maker Grail after antitrust battles

(Reuters) - Gene sequencing company Illumina said on Sunday it will divest cancer diagnostic test maker Grail after the companies battled both U.S. and ...

Company News and Releases - Illumina Inc., ILMN (NAS ...

Illumina to Shed Cancer-Test Maker Grail After Antitrust Battle The Wall Street Journal Interactive Edition. 08:16 PM ET. Illumina to sell cancer-test maker ...

EC Approves Illumina's Plan to Divest Cancer Diagnostics Maker ...

... cancer test maker Grail, marking the end of a drawn-out antitrust battle with regulators. The EC said it accepted the “restorative measures” which require ...

Inside Illumina's brutal proxy fight with Carl Icahn | Fortune

... test years after Illumina created and spun off Grail. The startup ... Grail appeared less risky since it produced cancer tests, not sequencers.

Illumina in the News | What others say about us and our technology

The $100 Genome: Where's the Limit? 12 Apr 2024, Reuters, EU approves Illumina's plan to divest cancer test maker Grail. 10 Apr 2024, San Diego Union Tribune ...